Parmax Pharma Ltd

Parmax Pharma Board Meeting Date

Parmax Pharma Ltd scheduled a board meeting on May 30, 2026, to approve audited financial results for fiscal 2026. The trading window remains closed for insiders.

Parmax Pharma Annual General Meeting

Parmax Pharma Limited has scheduled an Extra Ordinary General Meeting on May 27, 2026. Key agenda items include the appointment of three non-executive directors and the re-appointment of Mr. Umang Gosalia as Managing Director for five years. Remote e-voting is available from May 24 to May 26, 2026.

Parmax Pharma Management Change

Parmax Pharma Ltd has approved the re-appointment of Dr. Umang Gosalia (DIN: 05153830) as Managing Director for a five-year term starting June 28, 2026. Dr. Gosalia, associated with the firm since 2016, oversees production activities. The appointment is subject to shareholder approval at the upcoming general meeting.

Execution

5 years

Parmax Pharma Debt & Borrowing: ₹7.92 Cr

Parmax Pharma Ltd submitted its initial disclosure regarding the Large Corporate framework for the financial year. The company reported outstanding borrowings of ₹7.92 Crore and confirmed it does not meet the criteria to be classified as a Large Corporate under SEBI norms.

Value

₹7.92 Cr

Parmax Pharma Q3 FY26 Results: Net Loss of ₹0.7 Cr, Loss Widens

Parmax Pharma Ltd reported a net loss of ₹0.7 Cr for Q3 FY26.

Key figure

Net loss ₹0.7 Cr